Open AccessDual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis
Author(s) -
Aníbal Samael Méndez-Clemente,
Alejandro BravoCuéllar,
Salvador GonzálezOchoa,
Maria SantiagoMercado,
Luis Arturo Palafox-Mariscal,
Luis Felipe JaveSuárez,
Fabiola SolorzanoIbarra,
Marı́a Martha Villaseñor-Garcı́a,
Pablo César Ortiz-Lazareno,
Georgina HernándezFlores
Publication year - 2022
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or.2022.8349
Subject(s) - clonogenic assay , cancer research , vimentin , lncap , biology , prostate cancer , chemokine , cell migration , immunology , cancer , medicine , cell , immunohistochemistry , inflammation , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom